Raphael Pharmaceutical (RAPH) Income from Continuing Operations (2020 - 2024)
Raphael Pharmaceutical (RAPH) reported Income from Continuing Operations of 1932000.0 for Q4 2024, down 70.07% on a YoY basis from 6455152.94 in Q1 2024, and down 505.64% sequentially from 319000.0 in Q3 2024.
Raphael Pharmaceutical (RAPH) Income from Continuing Operations (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 5 years of Income from Continuing Operations data on file, last reported at 1932000.0 in Q4 2024.
- For the quarter ending Q4 2024, Income from Continuing Operations fell 70.07% year-over-year to 1932000.0; the trailing twelve-month figure through Dec 2024 stood at 3047000.0 (down 19.87% YoY), and the FY2025 full-year result was 3232000.0, down 6.07% from the prior year.
- Income from Continuing Operations eased to 1932000.0 in Q4 2024, from 319000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 175000.0 in Q1 2022 to a low of 1932000.0 in Q4 2024.
- A 5-year average of 758235.29 and a median of 419000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 371.95% in 2021 and surged 56.24% in 2024, its largest moves.
- Tracing RAPH's Income from Continuing Operations over 5 years: stood at 385000.0 in 2020, then plunged by 371.95% to 1817000.0 in 2021, then dropped by 0.77% to 1831000.0 in 2022, then surged by 37.96% to 1136000.0 in 2023, then slumped by 70.07% to 1932000.0 in 2024.
- Business Quant data shows RAPH's Income from Continuing Operations at 1932000.0 in Q4 2024, 319000.0 in Q3 2024, and 249000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.93 Mn |
| Sep 30, 2024 | -319,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -547,000.00 |
| Dec 31, 2023 | -1.14 Mn |
| Sep 30, 2023 | -729,000.00 |
| Jun 30, 2023 | -419,000.00 |
| Mar 31, 2023 | -258,000.00 |
| Dec 31, 2022 | -1.83 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -612,000.00 |
| Mar 31, 2022 | -175,000.00 |
| Dec 31, 2021 | -1.82 Mn |
| Sep 30, 2021 | -418,000.00 |
| Jun 30, 2021 | -385,000.00 |
| Mar 31, 2021 | -252,000.00 |
| Dec 31, 2020 | -385,000.00 |